Market Overview

UPDATE: Goldman Sachs Downgrades Laboratory Corp. of America Holdings to Sell on Comparative Outlook

Share:
Related LH
Illumina, Warburg Pincus, Sutter Hill Ventures Form Helix With $100M+ in Financing Commitments
Earnings Scheduled For July 28, 2015
Henry Schein's Buyout Spree: 85% Stake in Jorgen Kruuse (Zacks)

Goldman Sachs reduced its rating on Laboratory Corp. of America Holdings (NYSE: LH) from Neutral to Sell with a $83 price target.

Goldman Sachs noted, "We downgrade LH shares to Sell from Neutral as we see better relative upside to the balance of our Tools and Diagnostics coverage universe. Our new 6-month price target of $83 (from $85) implies 1% upside (vs. 12% for the group on average). Our thesis is based on our view that (1) any volume upside driven from the Affordable Care Act (ACA) is likely to come at the cost of pricing and margins, (2) upside to consensus EPS will depend on an increasing amount of financial leverage, and (3) aggressive capital allocation is unlikely to drive significant multiple expansion."

Laboratory Corp. of America Holdings closed at $83.21 on Friday.

Latest Ratings for LH

DateFirmActionFromTo
Jun 2015KeyBancInitiates Coverage onOverweight
Apr 2015JP MorganMaintainsOverweight
Apr 2015JefferiesMaintainsHold

View More Analyst Ratings for LH
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (LH)

View Comments and Join the Discussion!

Get Benzinga's Newsletters